A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females

BMC Cancer

Volumn 5, Issue , 2005, Pages

  García, Normand ^a,c   Salamanca, Fabio ^a   Astudillo de la Vega, Horacio ^b   Curiel Quesada, Everardo ^c   Alvarado, Isabel ^b   Peñaloza, Rosenda ^a   Arenas, Diego ^a  

^a HOSPITAL DE PEDIATRÍA   (Mexico)

^b HOSPITAL DE ONCOLOGÍA   (Mexico)

^c National Polytechnics Institute   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN BCL 2; TUMOR PROTEIN; APOPTOSIS REGULATORY PROTEIN; BIK PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ARTICLE; BREAST BIOPSY; BREAST TUMOR; CANCER STAGING; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; DNA HYBRIDIZATION; DNA MICROARRAY; DNA SYNTHESIS; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MEXICO; MOLECULAR GENETICS; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLING; TISSUE DISTRIBUTION; TUMOR CELL LINE; VALIDATION PROCESS; ADULT; AGED; BIOSYNTHESIS; CLUSTER ANALYSIS; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; PROTEIN TERTIARY STRUCTURE;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; CYTOPLASM; DISEASE PROGRESSION; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MEXICO; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 26844542844     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-93     Document Type: Article

References (48)

1. SUIVE: Sistema Unico de Informacion para la Vigilancia Epidemiologica /DGE/SSA. Incidencia de casos nuevos de enfermedades por grupo de edad Estados Unidos Mexicanos. Registro Histopalógico de Neoplasias Malignas 2002 [http://www.dgepi.salud.gob.mx/diveent/RHNM.htm].
2. Cornelisse CJ, Kuipers-Dijkshoorn N, van Vliet M, Hermans J, Devilee P: Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss. Int J Cancer 1992, 50:544-548.
3. Pandis N, Jin Y, Gorunova L, Petersson C, Bardi G, Idvall I, Johansson B, Ingvar C, Mandahl N, Mitelman F: Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups. Genes Chromosomes Cancer 1995, 12:173-185.
4. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H: ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991, 6:137-143.
5. Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H: c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 1992, 51:687-691.
6. Bieche I, Lidereau R: Genetic alterations in breast cancer. Genes Chromosomes Cancer 1995, 14:227-251.
7. Phelan CM, Borg A, Cuny M, Crichton DN, Baldersson T, Andersen TI, Caligo MA, Lidereau R, Lindblom A, Seitz S, Kelsell D, Hamann U, Rio P, Thorlacius S, Papp J, Olah E, Ponder B, Bignon YJ, Scherneck S, Barkardottir R, Borresen-Dale AL, Eyfjord J, Theillet C, Thompson AM, Larsson C: Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res 1998, 58:1004-1012.
8. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y: BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994, 266:120-122.
9. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF: Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995, 10:1673-1675.
10. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994, 54:1298-1304.
11. Vorechovsky I, Luo L, Lindblom A, Negrini M, Webster AD, Croce CM, Hammarstrom L: ATM mutations in cancer families. Cancer Res 1996, 56:4130-4133.
12. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
13. Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adelaide J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B, Birnbaum D, Nguyen C: Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 2000, 9:2981-2991.
14. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
15. de Bono JS, Tolcher AW, Rowinsky EK: The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res 2003, 5:154-159.
16. Glanzer JG, Eberwine JH: Expression profiling of small cellular samples in cancer: less is more. Br J Cancer 2004, 90:1111-1114.
17. Desai KV, Kavanaugh CJ, Calvo A, Green JE: Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer. Endocr Relat Cancer 2002, 9:207-220.
18. Forus A, Sorlie T, Borresen-Dale AL, Myklebost O: [Microarray technology - potential in cancer research]. Tidsskr Nor Laegeforen 2001, 121:2498-2503.
19. Liu ET: Classification of cancers by expression profiling. Curr Opin Genet Dev 2003, 13:97-103.
20. Watanabe I, Toyoda M, Okuda J, Tenjo T, Tanaka K, Yamamoto T, Kawasaki H, Sugiyama T, Kawarada Y, Tanigawa N: Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods. Jpn J Cancer Res 1999, 90:188-193.
21. Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, Berkowitz RS, Mok SC: Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000, 156:409-417.
22. Ioffe OB, Papadimitriou JC, Drachenberg CB: Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998, 29:1150-1159.
23. Astudillo H, Lopez T, Castillo S, Gariglio P, Benitez L: p53, Bcl-2, PCNA expression, and apoptotic rates during cervical tumorigenesis. Ann N Y Acad Sci 2003, 1010:771-774.
24. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002, 99:12963-12968.
25. Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326.
26. Verma S, Budarf ML, Emanuel BS, Chinnadurai G: Structural analysis of the human pro-apoptotic gene Bik: chromosomal localization, genomic organization and localization of promoter sequences. Gene 2000, 254:157-162.
27. Tong Y, Yang Q, Vater C, Venkatesh LK, Custeau D, Chittenden T, Chinnadurai G, Gourdeau H: The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domain. Mol Cancer Ther 2001, 1:95-102.
28. Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM, Hung MC: Systemic tumor suppression by the proapoptotic gene bik. Cancer Res 2002, 62:8-12.
29. Cotran R, Kumar V, Robins S, Schoen F: Pathologic basis of disease Fifth edition edition. Saunders; 1994.
30. Bioinformatics software solutions. J-Express 2002 [http://www.molmine.com].
31. Statsoft: TreeView & Cluster. 2000 [http://www.statsoft.com/textbook/stcluan.html].
32. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL: Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991, 66:817-822.
33. Lee SW: H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med 1996, 2:776-782.
34. O'Reilly PE, Raab SS, Niemann TH, Rodgers JR, Robinson RA: p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas. Mod Pathol 1997, 10:91-97.
35. Earnshaw WC, Martins LM, Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999, 68:383-424.
36. Porter AG, Janicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999, 6:99-104.
37. Mattson MP, Duan W, Pedersen WA, Culmsee C: Neurodegenerative disorders and ischemic brain diseases. Apoptosis 2001, 6:69-81.
38. Puthalakath H, Strasser A: Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002, 9:505-512.
39. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dorken B, Schulze-Osthoff K, Daniel PT: Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J 2003, 22:3580-3590.
40. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
41. Arena V, Martini M, Luongo M, Capelli A, Larocca LM: Mutations of the BIK gene in human peripheral B-cell lymphomas. Genes Chromosomes Cancer 2003, 38:91-96.
42. Klumpp S, Krieglstein J: Serine/threonine protein phosphatases in apoptosis. Curr Opin Pharmacol 2002, 2:458-462.
43. Verma S, Zhao LJ, Chinnadurai G: Phosphorylation of the proapoptotic protein BIK: mapping of phosphorylation sites and effect on apoptosis. J Biol Chem 2001, 276:4671-4676.
44. Mathai JP, Germain M, Marcellus RC, Shore GC: Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53. Oncogene 2002, 21:2534-2544.
45. Germain M, Mathai JP, Shore GC: BH-3-only BIK functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria. J Biol Chem 2002, 277:18053-18060.
46. Coultas L, Bouillet P, Stanley EG, Brodnicki TC, Adams JM, Strasser A: Proapoptotic BH3-only Bcl-2 family member Bik/Blk/Nbk is expressed in hemopoietic and endothelial cells but is redundant for their programmed death. Mol Cell Biol 2004, 24:1570-1581.
47. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dorken B, Brown R: Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. Blood 1999, 94:1100-1107.
48. Fay MJ, Longo KA, Karathanasis GA, Shope DM, Mandernach CJ, Leong JR, Hicks A, Pherson K, Husain A: Analysis of CUL-5 expression in breast epithelial cells, breast cancer cell lines, normal tissues and tumor tissues. Mol Cancer 2003, 2:40.